Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer

Key Points

• The aim is to compare the overall costs of two treatment regimens for EGFR-mutated non-small cell lung cancer.
• Cost analysis from a US payer's perspective
• Comparison of overall costs between two treatment groups
• Focus on first-line treatment outcomes
• Osimertinib plus platinum-pemetrexed shows substantially lower overall costs compared to amivantamab plus lazertinib.
• Cost advantages are notable for patients undergoing treatment for EGFR mutated non-small cell lung cancer.

Abstract